Novartis dissolves agreement to market Pear Therapeutics’ prescription digital therapeutics for substance/ opioid abuse

_______________ As San­doz returns mar­ket­ing rights for dig­i­tal ther­a­peu­tics to Pear, what does it mean for co-pro­­mote arrange­ments? (MM&M): “San­doz, the gener­ics divi­sion of Novar­tis, is alter­ing com­mer­cial course, return­ing mar­ket­ing duties for two pre­scrip­tion dig­i­tal ther­a­peu­tics (DTx) back to Pear Ther­a­peu­tics. The move, which some had antic­i­pat­ed, comes 18 months after the two signed…

Read More